S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
What to watch for as China's major political meeting of the year gets underway
Critical asset just had biggest fall on record (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
What to watch for as China's major political meeting of the year gets underway
Critical asset just had biggest fall on record (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
What to watch for as China's major political meeting of the year gets underway
Critical asset just had biggest fall on record (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
What to watch for as China's major political meeting of the year gets underway
Critical asset just had biggest fall on record (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
NASDAQ:LEGN

Legend Biotech (LEGN) Stock Price, News & Analysis

$65.53
+0.37 (+0.57%)
(As of 03/1/2024 ET)
Today's Range
$65.04
$66.17
50-Day Range
$55.06
$69.99
52-Week Range
$42.90
$77.32
Volume
372,096 shs
Average Volume
734,331 shs
Market Capitalization
$11.91 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$82.41

Legend Biotech MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.82 Rating Score
Upside/​Downside
25.8% Upside
$82.41 Price Target
Short Interest
Bearish
5.47% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.45mentions of Legend Biotech in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.47) to ($1.74) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.05 out of 5 stars

Medical Sector

634th out of 950 stocks

Pharmaceutical Preparations Industry

292nd out of 429 stocks


LEGN stock logo

About Legend Biotech Stock (NASDAQ:LEGN)

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia , gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

LEGN Stock Price History

LEGN Stock News Headlines

Legend Biotech Corporation (LEGN)
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Legend Biotech (NASDAQ:LEGN) Stock Price Up 4.7%
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
LEGN Mar 2024 65.000 call
LEGN Feb 2024 45.000 put
Legend Biotech: Solid Traction With Carvykti Rollout
RBC Capital Reaffirms Their Buy Rating on Legend Biotech (LEGN)
Analysts’ Top Healthcare Picks: Legend Biotech (LEGN), Xoma (XOMA)
Key Takeaways From Legend Biotech Analyst Ratings
See More Headlines
Receive LEGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Legend Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/20/2023
Today
3/02/2024
Next Earnings (Confirmed)
3/11/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:LEGN
Fax
N/A
Employees
1,390
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$82.41
High Stock Price Target
$94.00
Low Stock Price Target
$64.00
Potential Upside/Downside
+25.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.82
Research Coverage
11 Analysts

Profitability

Net Income
$-446,350,000.00
Net Margins
-207.24%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$117 million
Book Value
$4.54 per share

Miscellaneous

Free Float
181,753,000
Market Cap
$11.91 billion
Optionable
Optionable
Beta
0.04
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Ying Huang Ph.D. (Age 51)
    CEO & Director
  • Ms. Lori A. Macomber CPA (Age 53)
    Chief Financial Officer
  • Mr. Doug Wallace
    Vice President of Global Operations
  • Dr. Guowei Fang Ph.D.
    Chief Scientific Officer & Head of Business Development
  • Joanne Choi
    Senior Manager of Investor Relations
  • Mr. James Pepin J.D.
    General Counsel
  • Deborah Wong
    Executive Director of Strategic Marketing & Corporate Communications
  • Ms. Elaine Qian
    VP & Global Head of Human Resources
  • Ms. Liz Gosen
    Senior Vice President of Technical Operations
  • Dr. Yuhong Qiu Ph.D.
    Senior Vice President of Global Regulatory Affairs














LEGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Legend Biotech stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Legend Biotech in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" LEGN shares.
View LEGN analyst ratings
or view top-rated stocks.

What is Legend Biotech's stock price target for 2024?

11 Wall Street research analysts have issued twelve-month price objectives for Legend Biotech's shares. Their LEGN share price targets range from $64.00 to $94.00. On average, they expect the company's stock price to reach $82.41 in the next year. This suggests a possible upside of 25.8% from the stock's current price.
View analysts price targets for LEGN
or view top-rated stocks among Wall Street analysts.

How have LEGN shares performed in 2024?

Legend Biotech's stock was trading at $60.17 at the start of the year. Since then, LEGN stock has increased by 8.9% and is now trading at $65.53.
View the best growth stocks for 2024 here
.

When is Legend Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 11th 2024.
View our LEGN earnings forecast
.

How can I listen to Legend Biotech's earnings call?

Legend Biotech will be holding an earnings conference call on Monday, March 11th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Legend Biotech's earnings last quarter?

Legend Biotech Co. (NASDAQ:LEGN) announced its quarterly earnings results on Monday, November, 20th. The company reported ($0.17) earnings per share for the quarter, topping analysts' consensus estimates of ($0.31) by $0.14. The firm earned $96 million during the quarter, compared to the consensus estimate of $97.25 million. Legend Biotech had a negative trailing twelve-month return on equity of 40.03% and a negative net margin of 207.24%. The company's revenue was up 250.4% on a year-over-year basis.

What other stocks do shareholders of Legend Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Legend Biotech investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), CrowdStrike (CRWD), Lam Research (LRCX), ServiceNow (NOW), Peloton Interactive (PTON), QUALCOMM (QCOM), Applied Materials (AMAT), DocuSign (DOCU) and Etsy (ETSY).

When did Legend Biotech IPO?

(LEGN) raised $350 million in an initial public offering on Friday, June 5th 2020. The company issued 18,400,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, J.P. Morgan Securities and Jefferies acted as the underwriters for the IPO.

Who are Legend Biotech's major shareholders?

Legend Biotech's stock is owned by a number of institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (5.95%), Hhlr Advisors LTD. (3.29%), Capital World Investors (1.31%), Massachusetts Financial Services Co. MA (1.09%), Capital International Investors (1.00%) and Westfield Capital Management Co. LP (0.98%).

How do I buy shares of Legend Biotech?

Shares of LEGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LEGN) was last updated on 3/3/2024 by MarketBeat.com Staff